EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer

Alexandre de Nonneville, Florence Lerebours, Christophe Zemmour, Florence Dalenc, Christelle Levy, Thierry Petit, Marianne Leheurteur, Jean-Yves Pierga, Thomas Bachelot, Sylvain Ladoire, Frédéric Viret, Leonor Lopez Almeida und 5 weitere

European Journal of Cancer · 2026-12 · 249 · 117816

DOI: 10.1016/j.ejca.2026.117816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-12. Verfasst von Alexandre de Nonneville und 16 weiteren Autor:innen. Beteiligte Einrichtung: Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MSD France SAS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

HER2-negativeInflammatory breast cancerNeoadjuvant chemotherapyPD-L1Pathological complete responsePembrolizumab

Autor:innen und Institutionen

  • Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Department of Medical Oncology, Institut Curie, St Cloud, France.
  • Direction of Clinical Research and Investigation, Biostatistics and Methodology Unit, Institut Paoli-Calmettes, France.
  • Department of medical oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France.
  • Department of Medical Oncology, Centre François Baclesse, Caen, France.
  • Medical Oncology Department, Paul Strauss Cancer Centre, Strasbourg, France.

Förderung

  • MSD France SAS

Zitieren

APA

de Nonneville, A., Lerebours, F., Zemmour, C., Dalenc, F., Levy, C., Petit, T., Leheurteur, M., Pierga, J. Y., Bachelot, T., Ladoire, S., Viret, F., Almeida, L. L., Kaya, M., Boher, J. M., Bertucci, F., Charafe, E., & Gonçalves, A. (2026). PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer. European Journal of Cancer, 249, 117816. https://doi.org/10.1016/j.ejca.2026.117816

Vancouver

de Nonneville A, Lerebours F, Zemmour C, Dalenc F, Levy C, Petit T, et al. PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer. European Journal of Cancer. 2026;249:117816. doi:10.1016/j.ejca.2026.117816

BibTeX
@article{deNonneville2026,
  author = {de Nonneville, Alexandre and Lerebours, Florence and Zemmour, Christophe and Dalenc, Florence and Levy, Christelle and Petit, Thierry and Leheurteur, Marianne and Pierga, Jean-Yves and Bachelot, Thomas and Ladoire, Sylvain and Viret, Frédéric and Almeida, Leonor Lopez and Kaya, Muge and Boher, Jean-Marie and Bertucci, François and Charafe, Emmanuelle and Gonçalves, Anthony},
  title = {PELICAN-IPC 2015–016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {249},
  pages = {117816},
  doi = {10.1016/j.ejca.2026.117816}
}
Kostenlos starten →